Stroke: Thrombolysis and Antithrombotic Therapy

L. Creed Pettigrew, Michael R. Dobbs

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Antithrombotic therapy is the cornerstone of secondary stroke prevention. Medical practitioners have access to an armamentarium of drugs that include aspirin, clopidogrel, and aspirin-dipyridamole combinations, for the patient at high risk of atherothrombosis. Recombinant tissue plasminogen activator (rt-PA) is the only drug approved in the United States and Europe for the treatment of acute ischemic stroke. The usefulness of rt-PA has now been demonstrated up to 4.5 hours after the onset of stroke symptoms, for select patients. Alternative approaches to rt-PA for treatment of acute ischemic stroke include novel thrombolytic agents and combinations of platelet glycoprotein receptor antagonists with rt-PA. This chapter will review advances in the therapeutic management and prevention of ischemic stroke, including antithrombotic agents and thrombolytics.

Original languageEnglish
Title of host publicationTherapeutic Advances in Thrombosis, Second Edition
Number of pages13
StatePublished - Oct 3 2012


  • Abciximab
  • Aspirin
  • Blood platelets
  • Brain ischemia
  • Clopidogrel
  • Dipyridamole drug combination
  • Eptifibatide
  • Plasminogen activators
  • Stroke
  • Warfarin

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Stroke: Thrombolysis and Antithrombotic Therapy'. Together they form a unique fingerprint.

Cite this